Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Fig. 3

Influence of baseline proinflammatory markers on overall survival (OS) of patients who were readministered with tyrosine kinase inhibitors (a) OS between patients with high and low baseline neutrophil-to-lymphocyte ratio (NLR); (b) OS between patients with high and low lymphocyte-to-monocyte ratio (LMR)

Back to article page